Sage Therapeutics' rare disease drug fails mid-stage study

Sage Therapeutics

20/11/2024 11:36

Nov 20 (Reuters) - Sage Therapeutics  SAGE.O  said on
Wednesday its experimental drug failed to meet the main goal in
a mid-stage study testing the drug in patients with a rare,
genetic neurological condition called Huntington's disease.    

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini
Ganguli)
 ((Mariam.ESunny@thomsonreuters.com;))